Statins have been shown to be very effective and safe in numerous randomized clinical trials, and became the implacable first-line treatment against atherogenic dyslipidemia. However, even with optimal statin treatment, 60% to 80% of residual cardiovascular risk still exists. The patients with familial hypercholesterolemia which results in extremely high level of low density lipoprotein cholesterol (LDL-C) level and the patients who are intolerant or unresponsive to statins are the other hurdles of statin treatment. Recently, new classes of lipid-lowering drugs have been developed and some of them are available for the clinical practice. The pro-protein convertase subtilisin/kexintype 9 (PCSK9) inhibitor increases the expression of low density lipoprotein (LDL) receptor in hepatocytes by enhancing LDL receptor recycling. The microsomal triglyceride transport protein (MTP) inhibitor and antisense oligonucleotide against apolipoprotein B (ApoB) reduce the ApoB containing lipoprotein by blocking the hepatic very low density lipoprotein synthesis pathway. The apolipoprotein A1 (ApoA1) mimetics pursuing the beneficial effect of high density lipoprotein cholesterol and can reverse the course of atherosclerosis. ApoA1 mimetics had many controversial clinical data and need more validation in humans. The PCSK9 inhibitor recently showed promising results of significant LDL-C lowering in familial hypercholesterolemia (FH) patients from the long-term phase III trials. The MTP inhibitor and antisesnse oligonucleotide against ApoB were approved for the treatment of homozygous FH but still needs more consolidated evidences about hepatic safety such as hepatosteatosis. We would discuss the benefits and concerns of these new lipid-lowering drugs anticipating additional benefits beyond statin treatment.

Citations

Citations to this article as recorded by  

• Role of PCSK9 inhibitors in the management of dyslipidaemia
  Tiny Nair
  Indian Heart Journal.2024; 76: S44.     CrossRef
• Targeting Lipoprotein(a): Can RNA Therapeutics Provide the Next Step in the Prevention of Cardiovascular Disease?
  Henriette Thau, Sebastian Neuber, Maximilian Y. Emmert, Timo Z. Nazari-Shafti
  Cardiology and Therapy.2024; 13(1): 39.     CrossRef
• UHPLC Specific Method for Simultaneous Determination of Probable Impurities of Ezetimibeand Simvastatin in Combined Dosage Form
  Anantha Lakshmi Vadivelu, Sathapathy Panduranga Vittal, Duvvuri Suryakala
  Oriental Journal Of Chemistry.2024; 40(1): 228.     CrossRef
• PCSK9 and Lipid Metabolism: Genetic Variants, Current Therapies, and Cardiovascular Outcomes
  Daniela Grejtakova, Iveta Boronova, Jarmila Bernasovska, Stefano Bellosta
  Cardiovascular Drugs and Therapy.2024;[Epub]     CrossRef
• LC‐MS based metabolite profiling, in‐vitro antioxidant and in‐vivo antihyperlipidemic activity ofNigella sativaextract
  Amit Kumar Shrivastava, Laxmi Shrestha, Buddhi Raj Pokhrel, Bishal Joshi, Gopal Lamichhane, Bojana Vidović, Niranjan Koirala
  eFood.2023;[Epub]     CrossRef
• Development of New Genome Editing Tools for the Treatment of Hyperlipidemia
  Giulio Preta
  Cells.2023; 12(20): 2466.     CrossRef
• High residual cardiovascular risk after lipid-lowering: prime time for Predictive, Preventive, Personalized, Participatory, and Psycho-cognitive medicine
  E. Reijnders, A. van der Laarse, J. W. Jukema, C. M. Cobbaert
  Frontiers in Cardiovascular Medicine.2023;[Epub]     CrossRef
• Riesgo residual. Conclusiones
  Ángel Cequier, José Luis Zamorano
  Revista Española de Cardiología Suplementos.2023; 23: 25.     CrossRef
• Anti-hyperglycemic, anti-hyperlipidemic, and anti-inflammatory effect of the drug Guggulutiktaka ghrita on high-fat diet-induced obese rats
  Samreen M. Sheik, Pugazhandhi Bakthavatchalam, Revathi P. Shenoy, Basavaraj S. Hadapad, Deepak Nayak M, Monalisa Biswas, Varashree Bolar Suryakanth
  Journal of Ayurveda and Integrative Medicine.2022; 13(3): 100583.     CrossRef
• New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins
  Kyuho Kim, Henry N. Ginsberg, Sung Hee Choi
  Diabetes & Metabolism Journal.2022; 46(4): 517.     CrossRef
• A New Modality in Dyslipidemia Treatment: Antisense Oligonucleotide Therapy
  Kyuho Kim, Sung Hee Choi
  Journal of Lipid and Atherosclerosis.2022; 11(3): 250.     CrossRef
• Tyramine exerts hypolipidemic and anti-obesity effects in vivo
  Thamires Maria Fontenele Morais, Tiago Sousa Melo, Mariana Brito Dantas, Jamile Magalhães Ferreira, Daniel Freire de Sousa, Emanuel Paula Magalhães, Ramon Róseo Paula Pessoa Bezerra de Menezes, Otília Deusdênia Loiola Pessoa, Mariana Lima Feitosa, Francis
  Brazilian Journal of Pharmaceutical Sciences.2022;[Epub]     CrossRef
• Statin adherence and risk of all-cause, cancer, and cardiovascular mortality among dyslipidemia patients: A time-dependent analysis
  Young Ran Lee, Sarah Soyeon Oh, Sung-In Jang, Eun-Cheol Park
  Nutrition, Metabolism and Cardiovascular Diseases.2020; 30(12): 2207.     CrossRef
• Efficient reabsorption of transintestinally excreted cholesterol is a strong determinant for cholesterol disposal in mice
  Ivo P. van de Peppel, Anna Bertolini, Theo H. van Dijk, Albert K. Groen, Johan W. Jonker, Henkjan J. Verkade
  Journal of Lipid Research.2019; 60(9): 1562.     CrossRef
• Pharmacological Strategies beyond Statins: Ezetimibe and PCSK9 Inhibitors
  Jah Yeon Choi, Jin Oh Na
  Journal of Lipid and Atherosclerosis.2019; 8(2): 183.     CrossRef
• Effects of silymarin supplementation on blood lipids: A systematic review and meta‐analysis of clinical trials
  Hamed Mohammadi, Amir Hadi, Arman Arab, Sajjad Moradi, Mohammad Hossein Rouhani
  Phytotherapy Research.2019; 33(4): 871.     CrossRef
• Change in ALT levels after administration of HMG‐CoA reductase inhibitors to subjects with pretreatment levels three times the upper normal limit in clinical practice
  Hyunah Kim, Hyeseon Lee, Tong Min Kim, So Jung Yang, Seo Yeon Baik, Seung‐Hwan Lee, Jae‐Hyoung Cho, Hyunyong Lee, Hyeon Woo Yim, In Young Choi, Kun‐Ho Yoon, Hun‐Sung Kim
  Cardiovascular Therapeutics.2018;[Epub]     CrossRef
• Host-targeting therapies for hepatitis C virus infection: current developments and future applications
  Emilie Crouchet, Florian Wrensch, Catherine Schuster, Mirjam B. Zeisel, Thomas F. Baumert
  Therapeutic Advances in Gastroenterology.2018;[Epub]     CrossRef
• New and Future Parenteral Therapies for the Management of Lipid Disorders
  Roberto Garcia, Jaime Burkle
  Archives of Medical Research.2018; 49(8): 538.     CrossRef
• NEW DRUGS FOR THE TREATMENT OF DYSLIPIDEMIA
  Aleksandra Novaković, Marija Marinko, Ivan Stojanović, Dragoslav Nenezić, Predrag Milojević, Vladimir Kanjuh
  Acta Medica Medianae.2018; 57(1): 54.     CrossRef
• Effects of diethylene glycol dibenzoate and Bisphenol A on the lipid metabolism of Danio rerio
  Stefania Santangeli, Valentina Notarstefano, Francesca Maradonna, Elisabetta Giorgini, Giorgia Gioacchini, Isabel Forner-Piquer, Hamid R. Habibi, Oliana Carnevali
  Science of The Total Environment.2018; 636: 641.     CrossRef
• Cardiac autonomic neuropathy: Risk factors, diagnosis and treatment
  Victoria A Serhiyenko, Alexandr A Serhiyenko
  World Journal of Diabetes.2018; 9(1): 1.     CrossRef
• Krüppel-like factor 14, a coronary artery disease associated transcription factor, inhibits endothelial inflammation via NF-κB signaling pathway
  Wenting Hu, Haocheng Lu, Jifeng Zhang, Yanbo Fan, Ziyi Chang, Wenying Liang, Huilun Wang, Tianqing Zhu, Minerva T. Garcia-Barrio, Daoquan Peng, Y. Eugene Chen, Yanhong Guo
  Atherosclerosis.2018; 278: 39.     CrossRef
• Strategies for the use of nonstatin therapies
  Angela Pirillo, Giuseppe D. Norata, Alberico L. Catapano
  Current Opinion in Lipidology.2017; 28(6): 458.     CrossRef
• The efficacy advantage of evolocumab (AMG 145) dosed at 140 mg every 2 weeks versus 420 mg every 4 weeks in patients with hypercholesterolemia: Evidence from a meta-analysis
  Xiao-Xiao He, Rong Zhang, Pei-Yuan Zuo, Yu-Wei Liu, Xiang-Nan Zha, Sheng-Shuai Shan, Cheng-Yun Liu
  European Journal of Internal Medicine.2017; 38: 52.     CrossRef
• The Potential Therapeutic Application of Peptides and Peptidomimetics in Cardiovascular Disease
  Carlota Recio, Francesco Maione, Asif J. Iqbal, Nicola Mascolo, Vincenzo De Feo
  Frontiers in Pharmacology.2017;[Epub]     CrossRef
• Emerging biologic therapies for hypercholesterolaemia
  Giacomo Pucci, Arrigo F Cicero, Claudio Borghi, Giuseppe Schillaci
  Expert Opinion on Biological Therapy.2017; 17(9): 1077.     CrossRef
• ANMCO/ISS/AMD/ANCE/ARCA/FADOI/GICR-IACPR/SICI-GISE/SIBioC/SIC/SICOA/SID/SIF/SIMEU/SIMG/SIMI/SISA Joint Consensus Document on cholesterol and cardiovascular risk: diagnostic–therapeutic pathway in Italy
  Michele Massimo Gulizia, Furio Colivicchi, Gualtiero Ricciardi, Simona Giampaoli, Aldo Pietro Maggioni, Maurizio Averna, Maria Stella Graziani, Ferruccio Ceriotti, Alessandro Mugelli, Francesco Rossi, Gerardo Medea, Damiano Parretti, Maurizio Giuseppe Abr
  European Heart Journal Supplements.2017; 19(suppl_D): D3.     CrossRef
• Rev-erb regulation of cholesterologenesis
  Sadichha Sitaula, Jinsong Zhang, Fernanda Ruiz, Thomas P. Burris
  Biochemical Pharmacology.2017; 131: 68.     CrossRef
• Novel lipid modifying drugs to lower LDL cholesterol
  Arjen J. Cupido, Laurens F. Reeskamp, John J.P. Kastelein
  Current Opinion in Lipidology.2017; 28(4): 367.     CrossRef
• 2017 Position Paper of the Italian Society for Cardiovascular Prevention (SIPREC) for an Updated Clinical Management of Hypercholesterolemia and Cardiovascular Risk: Executive Document
  Massimo Volpe, Roberto Volpe, Giovanna Gallo, Vivianne Presta, Giuliano Tocci, Emanuela Folco, Andrea Peracino, Elena Tremoli, Bruno Trimarco
  High Blood Pressure & Cardiovascular Prevention.2017; 24(3): 313.     CrossRef
• Sobetirome: the past, present and questions about the future
  Jan Lammel Lindemann, Paul Webb
  Expert Opinion on Therapeutic Targets.2016; 20(2): 145.     CrossRef
• Role of growth hormone-releasing hormone in dyslipidemia associated with experimental type 1 diabetes
  Maritza J. Romero, Rudolf Lucas, Huijuan Dou, Supriya Sridhar, Istvan Czikora, Eby M. Mosieri, Ferenc G. Rick, Norman L. Block, Subbaramiah Sridhar, David Fulton, Neal L. Weintraub, Zsolt Bagi, Andrew V. Schally
  Proceedings of the National Academy of Sciences.2016; 113(7): 1895.     CrossRef
• Recent trends in and new data on the epidemiology and prevention of non-communicable diseases
  S. A. Boytsov
  Terapevticheskii arkhiv.2016; 88(1): 4.     CrossRef
• Cellular Model of Atherogenesis Based on Pluripotent Vascular Wall Pericytes
  Ekaterina A. Ivanova, Alexander N. Orekhov, Agnes L. Nishimura
  Stem Cells International.2016;[Epub]     CrossRef
• Pre-treatment with simvastatin prevents the induction of diet-induced atherosclerosis in a rabbit model
  Nikolaos Oikonomidis, Nikolaos Kavantzas, Laskarina-Maria Korou, Panagiotis Konstantopoulos, Vasilios Pergialiotis, Evangelos Misiakos, Ioannis Rizos, Christos Verikokos, Despina N. Perrea
  Biomedical Reports.2016; 5(6): 667.     CrossRef
• Prevention of oxLDL uptake leads to decreased atherosclerosis in hematopoietic NPC1-deficient Ldlr−/− mice
  Mike L.J. Jeurissen, Sofie M.A. Walenbergh, Tom Houben, Marion J.J. Gijbels, Jieyi Li, Tim Hendrikx, Yvonne Oligschlaeger, Patrick J. van Gorp, Christoph J. Binder, Marjo M.P.C. Donners, Ronit Shiri-Sverdlov
  Atherosclerosis.2016; 255: 59.     CrossRef